NurExone Biologic Inc.

Recent News

  • NurExone Announces Securities for Debt Settlement

    Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has agreed to settle debts in the amount of CAD$46,523.69 with the issuance of 122,430 common shares of the Company at a deemed price of CAD$0.38 per share.These debts were incurred prior to the recent Reverse Takeover Transaction following which...

    2022-11-24 7:17 PM EST
  • NurExone Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Calgary, Alberta--(Newsfile Corp. - November 24, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, released a corporate update and reported financial results for the quarter ended September 30, 2022."Obtaining U.S. FDA approval for our drug platform remains a priority for NurExone and we intend to continue working towards expediting this process by submitting a Pre-IND meeting request," said Dr. Lior...

    2022-11-24 8:00 AM EST
  • NurExone Announces Completion of Securities for Debt Settlements

    Calgary, Alberta--(Newsfile Corp. - November 8, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (formerly, EnerSpar Corp. or "EnerSpar") (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is announcing today that it has completed its securities for debt settlements, previously announced by the Company on September 1, 2022 and September 19, 2022. The Company agreed to settle debts in the aggregate amount of CAD$136,155.83 with the issuance of 170,195 common...

    2022-11-08 5:01 PM EST
  • NurExone Announces Plan to Submit Pre-Investigational New Drug Meeting Request to U.S. Food and Drug Administration

    The U.S. Food and Drug Administration (FDA) informed NurExone that it is at the appropriate stage of its product development for a pre-Investigational New Drug (pre-IND) meetingA pre-IND meeting could potentially shorten the regulatory timeline for the launch of NurExone's ExoTherapy into the U.S. market.Calgary, Alberta--(Newsfile Corp. - November 2, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, is pleased...

    2022-11-02 8:00 AM EDT
  • NurExone Announces Productivity and Quality Pilot Results of Patent-Pending Process for 3D Scaled Up Exosome Production

    Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy ("ExoTherapy") for patients with traumatic spinal cord injuries, announced today results of an internal productivity and quality pilot that was completed by the Company and the Technion - Israel Institute of Technology in Q2 2022 pursuant to the previously announced Sponsor Research Agreement, showing that its innovative and proprietary production process has the potential...

    2022-10-26 9:00 AM EDT
  • NurExone Biologic to Participate in 2022 Bio-Europe Conference

    Calgary, Alberta--(Newsfile Corp. - October 20, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company will be participating in the upcoming 2022 Bio-Europe Conference ("Bio-Europe") in Leipzig, Germany, which commences on October 24th and ends on October 26th.Bio-Europe is regarded as one of Europe's largest gathering of professionals in the biopharma industry.1 Over 4000 attendees...

    2022-10-20 8:00 AM EDT
  • UPDATE: NurExone Signs Letter of Intent with Nanometrix for Its Exosome and Cargo Molecular Profiling AI-Driven Technology

    Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company's wholly-owned subsidiary, NurExone Biologic Ltd., signed a non-binding...

    2022-10-12 12:55 PM EDT
  • NurExone Signs Letter of Intent with Nanometrix For its Exosome and Cargo Molecular Profiling AI-Driven Technology

    Both companies will collaborate to improve NurExone's drug development stages, from R&D to Quality AssuranceCompany to host an investor webinar on Thursday, October 20th, 2022 at 11:00 AM ESTCalgary, Alberta and Oxford, United Kingdom--(Newsfile Corp. - October 12, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to announce that the Company's wholly-owned subsidiary, NurExone Biologic Ltd., signed a non-binding...

    2022-10-12 9:00 AM EDT